Apomorphine protects against MPTP-induced neurotoxicity in mice

Movement Disorders

Volumn 14, Issue 4, 1999, Pages 612-618

  Grünblatt, Edna ^a   Mandel, Silvia ^a   Berkuzki, Tamara ^a   Youdim, M B H ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b B Rappaport Fam Med Sci Building ^*  (Israel)

Author keywords

Apomorphine; Dopamine; Iron; Monoamine oxidase A and B; MPTP (N methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Parkinson's disease; Radical scavenging; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; DOPAMINE; OXYGEN RADICAL; SCAVENGER; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME KINETICS; IRON CHELATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

EID: 0343550312     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6     Document Type: Article

References (42)

1. Youdim MBH, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993; 8:1-12.
2. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-806.
3. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MBH, eds. Neurodegeneration and Neuroprotection in Parkinson's Disease. London: Academic Press, 1996:24-45.
4. Olanow CW, Youdim MBH. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MBH, eds. Neurodegeneration and Neuroprotection in Parkinson's Disease. London: Harcourt Brace & Co, 1996:50-67.
5. Cohen G, Werner P. Free radicals oxidative stress and neurodegeneration. In: Calne DB, ed. Neurodegenerative Disorders. Philadelphia, PA: WB Saunders, 1994:139-162.
6. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal neurones. J Neurochem 1991; 56:1441-1444.
7. Ben-Shachar D, Youdim MBH. Intranigral iron injection induces behavioral and biochemical 'parkinsonism' in rats. J Neurochem 1991;57:2133-2135.
8. Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 1994;130:82-94.
9. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
10. Matthews RT, Yang L, Beal M. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 1997;143:282-286.
11. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43.
12. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993;7:121-128.
13. Colzi A, Turner K, Lee AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
14. Gassen M, Glinka Y, Pinchasi B, Youdim MBH. Apomorphine is highly potent free radical scavenger in rat mitochondrial fraction. Eur J Pharmacol 1996;308:219-225.
15. Gassen M, Gross A, Youdim MBH. Apomorphine enantiomers protect pheochromocytoma (PC 12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 1998;13:242-248.
16. 2-induced cell death. Adv Pharmacol 1998; 42:320-324.
17. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
18. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994;657:207-213.
19. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998;12:905-912.
20. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996;48:1-19.
21. Mochizuki H, Imai H, Endo K, et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced hemiparkinsonism in monkeys. Neurosci Lett 1994;168:251-253.
22. Temlett JA, Landsberg JP, Watt F, Grime GW. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe element microanalysis. J Neurochem 1994;62:134-146.
23. Di Monte D, Sandy MS, Smith MT. Increase efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 1987;148:153-160.
24. Singer TP, Castagnoli N Jr, Ramsay RR, Treor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;49:1-8.
25. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 1997;104:469-481.
26. Santiago M, Matarredona ER, Granero L, Cano J, Machado A. Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals. J Neurochem 1997;68:732-738.
27. Cadet JL, Katz M, Jackson-Lewis V, Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989;476:5-10.
28. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 1992;29: 699-701.
29. Glinka Y, Tipton KF, Youdim MBH. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 1996;66:2004-2010.
30. Glinka Y, Gassen M, Youdim MBH. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 1997;50:55-66.
31. Ben-Shachar D, Youdim MBH. Selectivity of melanized nigrastriatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J Neural Transm Suppl 1990;29:251-258.
32. Otsuka S, Kobayashi Y. A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 1964;13:995-1006.
33. Sam EE, Verbeke N. Free radical scavenging properties of apomorphine enantiomers and dopamine - possible implication in their mechanism of action in parkinsonism. J Neural Transm Park Dis Dement Sect 1995;10:115-127.
34. Sam E, Jeanjean AP, Maloteaux JM, Verbeke N. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20:27-33.
35. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease [Review]. J Neural Transm Suppl 1995;45:137-141.
36. Zigmond MJ, Berger TW, Grace AA, Stricker EM. Compensatory responses to nigrostriatal bundle injury. Mol Chem Neuropathol 1989;10:185-200.
37. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 1983;322:198-202.
38. Borbe HO, Niebch G, Nickel B. Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethylselegiline in the rat. J Neural Transm Suppl 1990;32:131-137.
39. Gassen M, Youdim MBH. Free radical scavengers: chemical concepts and clinical relevance. J Neural Transm 1999. In press.
40. Monteiro HP, Winterbourn CC. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 1989;38:4177-4182.
41. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994;660:8-18.
42. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochem Biophys Acta 1996;1316:160-168.